Sign in
INMB Stock Price, Chart, Stats & News
INmune Bio, Inc.
Save
INmune Bio, Inc. (INMB) does not currently pay a dividend.
53.97M
Market cap
–
Current P/E
–
Forward P/E
INMB chart
Fundamentals
Gross margin | 44.00% |
Operating margin | -102752.00% |
Pretax margin | -99774.00% |
Net margin | -99774.00% |
Effective tax rate | – |
ROA | -149.55% |
ROE | -172.00% |
D/E | 0.04x |
Interest coverage ratio | – |
INMB valuation
P/E | – |
P/S | 595.51x |
P/B | 1.17x |
P/CF | -0.97x |
P/FCF | -0.94x |
P/OCF | -0.97x |
PEG | -0.04x |
EV multiple | -1.68x |
About
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases.
Similar securities
Based on sector and market capitalization
Report issue